financialpost.com
Open in
urlscan Pro
34.107.199.243
Public Scan
URL:
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/fsd-pharma-expands-research-and-clinical-...
Submission: On November 17 via api from GB — Scanned from GB
Submission: On November 17 via api from GB — Scanned from GB
Form analysis 4 forms found in the DOM
GET /search/
<form action="/search/" class="top-menu-search__form top-menu-search__form--hidden" id="top-menu-search__form" method="get"> <label class="visually-hidden" for="id_search_text">Search financialpost.com</label>
<div class="search-form form__group"> <input class="form__control" id="id_search_text" name="search_text" placeholder="Search " required="" type="text" value=""> <button class="button button--primary button--icon top-menu-search__form-submit"
type="submit"> <span aria-hidden="true" class="button__icon"> <svg height="16" viewBox="0 0 32 32" with="16">
<path
d="M 12 1 C 5.9418624 1 1 5.9418624 1 12 C 1 18.058138 5.9418624 23 12 23 C 14.250876 23 16.345333 22.314679 18.091797 21.146484 L 27.939453 30.994141 A 2.0002 2.0002 0 1 0 30.767578 28.166016 L 20.957031 18.355469 C 22.23773 16.557441 23 14.367054 23 12 C 23 5.9418624 18.058138 1 12 1 z M 12 3.8691406 C 16.507309 3.8691406 20.130859 7.4926906 20.130859 12 C 20.130859 16.507309 16.507309 20.130859 12 20.130859 C 7.4926906 20.130859 3.8691406 16.507309 3.8691406 12 C 3.8691406 7.4926906 7.4926906 3.8691406 12 3.8691406 z">
</path>
</svg> </span> <span class="button__text visually-hidden">Perform search</span> </button> </div>
</form>GET /search/
<form action="/search/" class="search-form--lg" method="get"> <label class="visually-hidden" for="id_search_text_top">Search financialpost.com</label>
<div class="search-form form__group"> <input class="form__control" id="id_search_text_top" name="search_text" placeholder="Search financialpost.com" required="" type="text" value=""> <button
class="button button--primary button--icon top-menu-search__form-submit" type="submit"> <span aria-hidden="true" class="button__icon"> <svg height="16" viewBox="0 0 32 32" with="16">
<path
d="M 12 1 C 5.9418624 1 1 5.9418624 1 12 C 1 18.058138 5.9418624 23 12 23 C 14.250876 23 16.345333 22.314679 18.091797 21.146484 L 27.939453 30.994141 A 2.0002 2.0002 0 1 0 30.767578 28.166016 L 20.957031 18.355469 C 22.23773 16.557441 23 14.367054 23 12 C 23 5.9418624 18.058138 1 12 1 z M 12 3.8691406 C 16.507309 3.8691406 20.130859 7.4926906 20.130859 12 C 20.130859 16.507309 16.507309 20.130859 12 20.130859 C 7.4926906 20.130859 3.8691406 16.507309 3.8691406 12 C 3.8691406 7.4926906 7.4926906 3.8691406 12 3.8691406 z">
</path>
</svg> </span> <span class="button__text visually-hidden">Perform search</span> </button> </div>
</form>#
<form action="#" aria-describedby="submitErrorFP_HeadlineNews submitSuccessFP_HeadlineNews" class="js-newsletter-form form-container" novalidate="">
<div class="form-container__field js-newsletter-email__field"> <label class="form__label" for="emailFP_HeadlineNews"> Email Address </label> <input aria-describedby="emailErrorFP_HeadlineNews" aria-invalid="false" aria-required="true"
autocomplete="email" class="form__control js-newsletter-email" id="emailFP_HeadlineNews" name="newsletterEmailFP_HeadlineNews" placeholder="youremail@email.com" required="" type="email">
<div class="form-container__message--error js-invalid-email" hidden="" id="emailErrorFP_HeadlineNews">
<ul class="errorlist">
<li> There was an error, please provide a valid email address. </li>
</ul>
</div>
</div> <button class="button button--primary" type="submit">Sign Up</button>
</form>Name: signInForm — POST https://postmedia.us.janraincapture.com/widget/traditional_signin.jsonp
<form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://postmedia.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate"
data-transactionid="7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" target="captureIFrame_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" accept-charset="UTF-8" next="{"noop":""}">
<div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div>
<div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input
id="capture_signIn_screen_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="capture_screen"><input
id="capture_signIn_js_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="js_version"><input
id="capture_signIn_transactionId_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" type="hidden" class="capture_transactionId_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h"
name="capture_transactionId"><input id="capture_signIn_form_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="form"><input
id="capture_signIn_flow_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="flow"><input
id="capture_signIn_client_id_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="dtc6exhr3gqccq68pu4rqghrvga3v36m" type="hidden" class="capture_client_id_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="client_id"><input
id="capture_signIn_redirect_uri_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="https://postmedia.us/?sso-redirect" type="hidden" class="capture_redirect_uri_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h"
name="redirect_uri"><input id="capture_signIn_response_type_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="token" type="hidden" class="capture_response_type_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h"
name="response_type"><input id="capture_signIn_flow_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="20210202143045091402" type="hidden" class="capture_flow_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h"
name="flow_version"><input id="capture_signIn_settings_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h"
name="settings_version"><input id="capture_signIn_locale_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="locale"><input
id="capture_signIn_recaptcha_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_7g83v78zfgbpgnd7sfo0ebt6z0u9w3zstbozld8h" name="recaptchaVersion">
<div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input
id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress">
<div class="capture_tip"></div>
<div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div>
<div class="capture_tip_error" data-elementname="signInEmailAddress" aria-live="polite"></div>
</div>
<div class="identity-modal__forgot-password">
<div class="identity-modal__forgot-password-link">
<a role="button" href="#" data-capturescreen="forgotPassword">Forgot Password?</a>
</div>
<div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input
id="capture_signIn_currentPassword" autocomplete="off" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword">
<div class="capture_tip"></div>
<div class="capture_tip_validating" data-elementname="currentPassword">Validating</div>
<div class="capture_tip_error" data-elementname="currentPassword" aria-live="polite"></div>
</div>
</div>
<button class="identity-modal__button capture_btn" type="submit">Sign In</button>
</form>Text Content
Skip to Content
Register Now
FP CryptoDecoded: Join us at our free crypto and blockchain events. FP
CryptoDecoded: Join us at our free crypto and blockchain events. Register now>
Manage Print Subscription
Sections
Search
Search financialpost.com
Perform search
Financial Post
Share
SHARE THIS STORY: FSD PHARMA EXPANDS RESEARCH AND CLINICAL ADVISORY BOARD WITH
APPOINTMENT OF WORLD-RENOWNED IMMUNOLOGIST AND CYTOKINE EXPERT DR. ELEANOR N.
FISH
* Copy Link
* Email
* Facebook
* Twitter
* Reddit
* LinkedIn
* Tumblr
Subscribe
Sign In
User My Account Toggle menu Close menu
Account Menu
* Profile
* Manage My Subscriptions
* Newsletters & Alerts
* Settings
* Customer Service
* FAQ
* Refer A Friend
* Sign Out
Main Menu
Search financialpost.com
Perform search
* News
* Election 2021
* Archives
* FP Energy
* Oil & Gas
* Renewables
* Electric Vehicles
* FP Finance
* Banking
* Insurance
* Fintech
* Cryptocurrency
* FP Investor
* Markets
* Personal Finance
* Family Finance
* Retirement
* Taxes
* High Net Worth
* MoneyWise Canada
* FP Economy
* FP Work
* FP Comment
* Newsletters
* Business Essentials
* MoneyWise Canada
* Borrowing Money
* Future Money
* Growing Money
* Refer a Friend
* More
* Innovation
* The Funding Portal
* FP Magazine
* FP500
* Real Estate
* Podcasts
* Video
* Information Technology
* Small Business
* Entrepreneur
* Commodities
* Agriculture
* Mining
* Shopping Essentials
* Home Living
* Style & Beauty
* Kitchen & Dining
* Personal Care
* Entertainment & Hobbies
* Gift Guide
* Obituaries
* Place a Notice
* Classifieds
* Place a Classifieds ad
* Working
* Advertise With Us
* News
* FP Energy
* FP Finance
* FP Investor
* FP Economy
* FP Work
* FP Comment
* Newsletters
* Business Essentials
* MoneyWise Canada
* Refer a Friend
ADVERTISEMENT
This advertisement has not loaded yet, but your article continues below.
*
*
*
* SHARE THIS STORY: FSD PHARMA EXPANDS RESEARCH AND CLINICAL ADVISORY BOARD
WITH APPOINTMENT OF WORLD-RENOWNED IMMUNOLOGIST AND CYTOKINE EXPERT DR.
ELEANOR N. FISH
* Copy Link
* Email
* Facebook
* Twitter
* Reddit
* LinkedIn
* Tumblr
This section is Partnership Content supplied by Business Wire
The content in this section is supplied by Business Wire for the purposes of
distributing press releases on behalf of its clients. Postmedia has not reviewed
the content.
BREADCRUMB TRAIL LINKS
1. PMN Press Releases
2. Business Wire News Releases
FSD PHARMA EXPANDS RESEARCH AND CLINICAL ADVISORY BOARD WITH APPOINTMENT OF
WORLD-RENOWNED IMMUNOLOGIST AND CYTOKINE EXPERT DR. ELEANOR N. FISH
Author of the article:
Business Wire
Publishing date:
Nov 16, 2021 • 16 hours ago • 4 minute read • Join the conversation
ARTICLE CONTENT
TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or
the “Company”), a life sciences holding company dedicated to building a
portfolio of assets and biotech solutions, today announced the appointment of
Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board.
Dr. Fish, an accomplished researcher in the areas of immunology and inflammatory
disorders, and member of the Government of Canada’s Expert Scientific Panel to
the Chief Scientific Advisor, brings key expertise to FSD Pharma that will
support the continued development of FSD-PEA, the Company’s proprietary
anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of
multiple sclerosis.
ADVERTISEMENT
Story continues below
This advertisement has not loaded yet, but your article continues below.
ARTICLE CONTENT
“I am delighted to welcome Dr. Eleanor Fish to our team,” said Dr. Lakshmi P.
Kotra, B.Pharm. (Hons), Ph.D., Chief Executive Officer of Lucid Psycheceuticals
Inc., FSD Pharma’s wholly-owned subsidiary. “A key aspect of Eleanor’s research
is to better understand the onset and treatment of autoimmune diseases, such as
multiple sclerosis and rheumatoid arthritis. Her expertise and insights will be
extremely valuable as we continue to advance our FSD-PEA and Lucid-MS programs,
and her decades of experience in translational research will greatly benefit
FSD’s current and future pipelines.”
Dr. Fish serves as a Professor in the Department of Immunology at the University
of Toronto; Associate Chair of International Initiatives and Collaborations at
the University of Toronto; and Emerita Scientist at the Toronto General Hospital
Research Institute of the University Health Network. She received a B.Sc. from
the U.K.’s University of Manchester, an M.Phil. from King’s College at the
University of London, and a Ph.D. from the Institute of Medical Sciences at the
University of Toronto. Dr. Fish has received numerous international awards
recognizing her scientific achievements and has authored more than 170
peer-reviewed scientific papers published in international journals.
“I am energized by this opportunity to assist FSD Pharma in advancing the
development of its next- generation therapeutics in pursuit of a healthier
world,” said Dr. Fish.
About FSD Pharma
FSD Pharma is a life sciences holding company with two wholly-owned subsidiaries
dedicated to building a portfolio of diversified therapeutic assets and
innovative healthcare and biotech services.
FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech
pharmaceutical R&D company focused on developing applications of its lead
compound, ultramicronized PEA, by down-regulating the cytokines to effectuate an
anti-inflammatory response.
Lucid Psycheceuticals Inc., a wholly-owned subsidiary, has exclusive worldwide
rights to novel compounds shown to prevent and potentially reverse the
biochemical mechanisms of progressive multiple sclerosis in multiple preclinical
animal models. Additionally, FSD is seeking to develop a unique psychoactive
(psychedelic-based) therapeutic aimed at addressing neurodegenerative disorders,
a multibillion-dollar mental health market. The Company hopes to quickly advance
its lead drug candidates through clinical trials.
ADVERTISEMENT
Story continues below
ARTICLE CONTENT
Forward Looking Information
Certain statements contained herein are “forward-looking statements.” Often, but
not always, forward-looking statement can be identified by the use of words such
as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”,
“anticipates”, “hopes”, “planned” or “believes”, or variations of such words and
phrases, or states that certain actions, events or results “may”, “could”,
“would”, “might”, “potentially” or “will” be taken, occur or be achieved.
Forward-looking statements contained in this press release include the comments
made with respect to advancing the Company’s research into Lucid-MS and
LUCID-PSYCH toward the clinic, including the anticipated launch a Phase 1
clinical trial of Lucid-MS by the end of 2022, and the efforts to advance
ultramicronized Palmitoylethanolamide and develop of applications therefor
evaluation of the commercial viability of its principal drug compound. FSD
cannot give any assurance that such forward-looking statements will prove to
have been correct. The reader is cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release.
Since forward-looking statements relate to future events and conditions, by
their very nature they require making assumptions and involve inherent risks and
uncertainties. The Company cautions that although it is believed that the
assumptions are reasonable in the circumstances, these risks and uncertainties
give rise to the possibility that actual results may differ materially from the
expectations set out in the forward-looking statements. Factors that may cause
such material differences include without limitation: the fact that the drug
development efforts of both Lucid and FSD BioSciences are at a very early stage;
the fact that preclinical drug development is uncertain, and the drug product
candidates of Lucid and FSD BioSciences may never advance to clinical trials;
the fact that results of preclinical studies and early-stage clinical trials may
not be predictive of the results of later stage clinical trials; the uncertain
outcome, cost, and timing of product development activities, preclinical studies
and clinical trials of Lucid and FSD BioSciences; the uncertain clinical
development process, including the risk that clinical trials may not have an
effective design or generate positive results; the potential inability to obtain
or maintain regulatory approval of the drug product candidates of Lucid and FSD
BioSciences; the introduction of competing drugs that are safer, more effective
or less expensive than, or otherwise superior to, the drug product candidates of
Lucid and FSD BioSciences; the initiation, conduct, and completion of
preclinical studies and clinical trials may be delayed, adversely affected, or
impacted by COVID-19 related issues; the potential inability to obtain adequate
financing; the potential inability to obtain or maintain intellectual property
protection for the drug product candidates of Lucid and FSD BioSciences; and
other risks. Further information regarding factors that may cause actual results
to differ materially are included in the Company’s annual and other reports
filed from time to time with the Canadian Securities Administrators on SEDAR (
www.sedar.com ) and with the U.S. Securities and Exchange Commission on EDGAR (
www.sec.gov ) under the heading “Risk Factors.” Any forward-looking statement
contained in this release speaks only as of its date. The Company does not
undertake to update any forward-looking statements, except to the extent
required by applicable securities laws.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20211116005845/en/
Contacts
Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8888
Investor Relations: Email: ir@fsdpharma.com , Website: www.fsdpharma.com
#distro
SHARE THIS ARTICLE IN YOUR SOCIAL NETWORK
*
*
*
* SHARE THIS STORY: FSD PHARMA EXPANDS RESEARCH AND CLINICAL ADVISORY BOARD
WITH APPOINTMENT OF WORLD-RENOWNED IMMUNOLOGIST AND CYTOKINE EXPERT DR.
ELEANOR N. FISH
* Copy Link
* Email
* Facebook
* Twitter
* Reddit
* LinkedIn
* Tumblr
ADVERTISEMENT
Story continues below
This advertisement has not loaded yet, but your article continues below.
FINANCIAL POST TOP STORIES
Sign up to receive the daily top stories from the Financial Post, a division of
Postmedia Network Inc.
Email Address
* There was an error, please provide a valid email address.
Sign Up
By clicking on the sign up button you consent to receive the above newsletter
from Postmedia Network Inc. You may unsubscribe any time by clicking on the
unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor
Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
THANKS FOR SIGNING UP!
A welcome email is on its way. If you don't see it, please check your junk
folder.
The next issue of Financial Post Top Stories will soon be in your inbox.
We encountered an issue signing you up. Please try again
TRENDING
1. BIG SHORT’S MICHAEL BURRY DELETES TWITTER ACCOUNT AFTER SPAT WITH ELON MUSK
2. BROOKFIELD FACES 'IMMINENT DEFAULT' ON CHICAGO OFFICE BUILDING
3. HOUSING MARKET HEATS BACK UP WITH BIGGEST JUMP IN SALES SINCE PANDEMIC BOOM
STARTED
4. JOE NATALE OUT AS ROGERS CEO, TO BE REPLACED BY FORMER CFO STAFFIERI
5. ENBRIDGE PARTIALLY SHUTS DOWN WESTCOAST GAS SYSTEM AMID B.C. FLOODING
THIS WEEK IN FLYERS
COMMENTS
Postmedia is committed to maintaining a lively but civil forum for discussion
and encourage all readers to share their views on our articles. Comments may
take up to an hour for moderation before appearing on the site. We ask you to
keep your comments relevant and respectful. We have enabled email
notifications—you will now receive an email if you receive a reply to your
comment, there is an update to a comment thread you follow or if a user you
follow comments. Visit our Community Guidelines for more information and details
on how to adjust your email settings.
0
CATEGORIES
* News
* FP Energy
* FP Finance
* FP Investor
* FP Economy
* FP Work
* FP Comment
* Newsletters
* Business Essentials
* MoneyWise Canada
* Refer a Friend
* Subscribe
--------------------------------------------------------------------------------
SECONDARY LINKS
MY ACCOUNT
* Subscriber Self-Serve
* ePaper
* Contact Us
ADVERTISE
* Advertise With Us
* Appointment Notice
* Content Works
* Partnerships
* Resources
CLASSIFIED
* Remembering
* Celebrating
* Classifieds Marketplace
* Careers
* FlyerCity
* Post a Classified ad
* Local Directory
SALES
* About Us
POSTMEDIA NETWORK
* National Post
* Regina Leader-Post
* Saskatoon StarPhoenix
* Windsor Star
* Ottawa Citizen
* Winnipeg Sun
* London Free Press
* Canada.com
* Canoe.com
* Driving.ca
* The Province
* Vancouver Sun
* Edmonton Journal
* Calgary Herald
* Montreal Gazette
* Toronto Sun
* Ottawa Sun
* Calgary Sun
* Edmonton Sun
National Post ❯
FOLLOW US
*
*
*
*
GIVE US SOME FEEDBACK!
--------------------------------------------------------------------------------
365 Bloor Street East, Toronto, Ontario, M4W 3L4
© 2021 Financial Post, a division of Postmedia Network Inc. All rights reserved.
Unauthorized distribution, transmission or republication strictly prohibited.
BOTTOM LINKS
Privacy - Updated Terms
Copyright
Digital Ad Registry
Sitemap
Contact us
NOTICE FOR THE POSTMEDIA NETWORK
This website uses cookies to personalize your content (including ads), and
allows us to analyze our traffic. Read more about cookies here. By continuing to
use our site, you agree to our Terms of Service and Privacy Policy.
OK
{* mergeAccounts {"custom": true} *}
MERGE ACCOUNTS
{| current_displayName |}
{| current_emailAddress |}
Postmedia already has a registered account for {| current_emailAddress |}
{| existing_displayName |}
{| existing_provider_emailAddress |}
Connect this session with your existing account? You will need to sign in to
your existing account.
Create account using {| current_provider |}
Validating
{| connect_button |} {| create_button |}
Privacy Terms
RESET PASSWORD
Please enter your account email address. We'll send you a link to reset your
password.
{* #forgotPasswordForm *} {* signInEmailAddress *} {* /forgotPasswordForm *}
Privacy Terms
RESET PASSWORD REQUESTED
We have sent you an email with instructions to reset your password. Your
existing password has not been changed.
Close
Privacy Terms
CREATE NEW PASSWORD
We didn't recognize that password reset code. Please enter your email below, and
we'll send you a new code to reset your password.
{* #resetPasswordForm *} {* signInEmailAddress *}
{* /resetPasswordForm *}
Privacy Terms
CREATE NEW PASSWORD
We've sent you an email with instructions to create a new password. Your
existing password has not been changed.
Close
Privacy Terms
RESET PASSWORD
{* #changePasswordFormNoAuth *} {* newPassword *} {* newPasswordConfirm *} {*
/changePasswordFormNoAuth *}
For a strong password you need...
Minimum 10 characters
A combination of letters and numbers
(a-z, A-Z, 0-9)
And special characters ($ @ # % ^ & * !)
Both passwords match
Privacy Terms
RESET PASSWORD
Your Password has been successfully updated!
Close
Privacy Terms
REGISTER FOR AN ACCOUNT
ALREADY HAVE AN ACCOUNT? SIGN IN
{* #socialRegistrationForm *}
{* firstName *} {* lastName *}
{* emailAddress *} {* displayName *} {* optInRegistration *} {* captcha *} {*
/socialRegistrationForm *}
By registering, I agree to Postmedia's Terms and Service and have read and
understood Postmedia's Privacy Policy.
Privacy Terms
REGISTER FOR AN ACCOUNT
ALREADY HAVE AN ACCOUNT? SIGN IN
{* loginWidget *}
OR REGISTER WITH EMAIL
{* #registrationForm *}
{* firstName *} {* lastName *}
{* emailAddress *} {* newPassword *} {* newPasswordConfirm *}
For a strong password you need...
Minimum 10 characters
A combination of letters and numbers
(a-z, A-Z, 0-9)
And special characters ($ @ # % ^ & * !)
Both passwords match
{* optInRegistration *} {* captcha *} {* /registrationForm *}
By registering, I agree to Postmedia's Terms and Service and have read and
understood Postmedia's Privacy Policy.
Privacy Terms
VERIFY EMAIL
We have sent you a confirmation email to {* emailAddressData *}. Please check
your inbox to verify your email address.
Close
Privacy Terms
DEACTIVATE ACCOUNT
Your account has been deactivated.
Close
Privacy Terms
ACCOUNT REACTIVATION FAILED
Sorry, we could not verify that email address.
Privacy Terms
ACCOUNT ACTIVATED
Your account has been reactivated.
Sign in
Privacy Terms
CHECK YOUR EMAIL TO ACTIVATE YOUR ACCOUNT
Thanks for registering. Please click the “activate” button in the email sent to
the address listed below to begin enjoying Financial Post access.
{* #resendVerificationForm *} {* signInEmailAddress *} {*
/resendVerificationForm *}
Privacy Terms
SIGN IN
WELCOME BACK
{* loginWidget *}
Switch Account
Privacy Terms
SIGN IN
WELCOME BACK
{* #signInForm *} {* signInEmailAddress *}
Forgot Password?
{* currentPassword *}
Sign In
{* /signInForm *}
Switch Account
Privacy Terms
SIGN IN TO MERGE ACCOUNTS
{* #signInForm *} {* signInEmailAddress *} {* currentPassword *} Sign In {*
/signInForm *}
Privacy Terms
RESEND VERIFICATION EMAIL
Sorry, we could not verify your email address. Please enter your email below,
and we'll resend the instructions for email verification.
{* #resendVerificationForm *} {* signInEmailAddress *}
{* /resendVerificationForm *}
Privacy Terms
ACTIVATION EMAIL SENT!
Please check your email for a link to verify your address.
Close
Privacy Terms
YOU'RE REGISTERED!
* Read local and national news
* Engage with other readers in our interactive comments sections
Start Reading!
<
close
SIGN IN
DON'T HAVE AN ACCOUNT? REGISTER NOW
Sign in using your account with
* Continue with Facebook
* Continue with Google
Social Login by Janrain
OR SIGN IN WITH EMAIL
We have updated our password requirements. If you recently have reset your
password, or you are signing in with your Facebook or Google account, simply
sign in to continue.
Otherwise, please reset your password to make it stronger and more secure.
Reset password now >
Email Address
Validating
Forgot Password?
Password
Validating
Sign In
Privacy Terms